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ABSTRACT
The effects of a general varicella vaccination programme on the incidence of herpes zoster are of major
public health importance. This review focuses on two key aspects, namely the relationship between
wild-type virus spread and the incidence of herpes zoster, as obtained from recent surveys, surveillance
and observational studies, and the results from mathematical population models. Although knowledge
is limited, close contact with varicella cases seems to have a protective effect. Thus, an increase in zoster
incidence after varicella immunisation is possible, but the extent is unknown because of the influence of
other factors independent of immunisation. Currently, vaccination effects estimated from mathematical
modelling depend strongly on pre-specified assumptions. In order to obtain more precise predictions,
the results of ongoing monitoring and clinical studies are awaited and further studies are suggested.
Vaccination recommendations can be adapted at any time to take account of further findings in this area.
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INTRODUCTION
A general varicella (i.e., chickenpox) vaccination
programme for all children aged 12–18 months,
and further catch-up strategies, were introduced
in the USA in 1996 [1]. No empirical baseline data
were available at that time regarding the impact
of a universal vaccination programme on varicella
epidemiology. Concerns have been raised about a
potential age-shift, i.e., an increase in the absolute
number of diagnosed varicella cases in older age
groups, in which varicella generally results in a
more severe disease course. Although the relative
number may increase, Klose et al. [2] and Banz
et al. [3] found no evidence indicating an age-shift
in primary varicella infection with immunisation
levels of > 50%. However, this may occur with
immunisation levels of < 50% [3], which is a
similar degree of coverage to that reported by
Panagiotopoulos et al. [4] for rubella vaccination
in Greece. Nevertheless, since the introduction of
universal varicella vaccination in the USA, no
general age-shift in varicella cases has been
observed to date [5].
A further concern is the potential initial
increase in herpes zoster incidence resulting from
a decrease in the spread of wild-type varicella
zoster virus (VZV) following vaccination. The
reasoning behind this is that virus shed from
varicella cases may inhibit reactivation of latent
virus, and thus protect latent-infected individuals
from developing herpes zoster. However, the
exact mechanism of reactivation is not known.
Three possible pathways should be considered, in
that virus shed from an infectious varicella case
either may or may not stimulate, or may inhibit,
the reactivation of latent virus [6]. Additional
factors such as ageing and immunocompetence
should also be taken into account.
Currently discussed risk factors for herpes
zoster have been summarised by Thomas and
Hall [7]. In order to determine the possible effects
of vaccination on the incidence of herpes zoster, it
is essential to know how much VZV reactivation
is caused by factors influenced by vaccination,
such as virus shedding, and how much is caused
by other factors uninfluenced by vaccination. The
issue is of major public health importance, both in
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countries that have already implemented a gen-
eral vaccination programme against varicella, and
in countries that are currently debating the imple-
mentation of such a programme.
This review describes empirical and analytical
methods for addressing two essential questions:
(1) what is the relationship between wild-type
virus spread and incidence of herpes zoster; and
(2) what is the influence of a general varicella
vaccination programme on herpes zoster inci-
dence? Factors influencing the reactivation of
VZV are discussed, as well as the potential risks
of reactivation following vaccination. An overall
keyword search in MEDLINE yielded 240 inter-
national publications in the years 1990–2004.
When keywords were restricted to the title, only
18 publications were found. In addition to an
essential paper from 1992 [6], Tables 1–3 give an
overview of the work reviewed and the issues
addressed in publications since 2000.
EMPIRICAL METHODS
The methods of investigation used in the studies
can be divided into two different groups:
statistical analysis of empirical data from the
pre-vaccination and post-vaccination eras, and
mathematical modelling of disease courses with
simulation techniques in analytical approaches.
Empirical data come mainly from England,
Wales, Canada and the USA in the form of
surveys and case reports. However, it is only
possible to make pre- and post-vaccination com-
parisons with data from the USA. In other
countries with no general varicella vaccination
programme, the influence of surrogates for virus
shedding and varicella contacts on herpes zoster
incidence is determined with odds ratios and
time-series analyses.
Various groups have studied hospital admis-
sion data to determine the baseline relationship
between varicella and herpes zoster incidence in
the pre-vaccination era [8,9]. An extensive Kaiser
Permanente Medical Care Program (KPMCP) in
Oakland, CA, USA was launched to specifically
evaluate a possible age-shift in future varicella
cases and to monitor the incidence of herpes
zoster [10]. Interim 6-year data from the KPMCP
study refer to herpes zoster hospitalisation rates
pre- and post-vaccination [11]. Gershon [5] repor-
ted varicella and herpes zoster surveillance data
and described the current situation in the USA.
Data were from the medical records of a Health
Maintenance Organization in Seattle and a state-
wide survey from Massachusetts. These studies
provided the first empirical data from the USA, a
country with an ongoing universal vaccination
programme. Goldman [12] reported the first
findings from active surveillance in Antelope
Valley, USA, for the years 2000 and 2001, and
the same author [13] estimated herpes zoster
incidence rates before widespread vaccination by
analysis of an adolescent survey in the same
district. The remaining studies in Tables 1–3 are
from countries without a general vaccination
programme against varicella and thus are not
influenced by vaccination campaigns.
ANALYTICAL METHODS
Simulation studies based on mathematical popu-
lation models have been initiated to predict the
possible impact of varicella vaccination on herpes
zoster incidence. Mathematical modelling is
Table 1. Studies on the relationship
between varicella and herpes zoster:
empirical and epidemiological stud-
ies
Study ⁄ Investigation Type Population Issues addressed
Ray et al. [11] Database
evaluation
HMO,
California, USA,
1994 and 2000
Hospitalisation rates related to varicella
and herpes zoster for 1994 (pre-licensure)
and 2000 (post-licensure)
Gershon [5] Survey,
medical
records
USA Varicella and herpes zoster surveillance
Goldman [12] Surveillance Antelope Valley,
California, USA,
2000 and 2001
Ascertainment-adjusted herpes zoster
incidence rates for children aged
< 10 years and individuals aged
10–19 years in the post-vaccination era
Goldman [13] Adolescent
survey
Antelope Valley,
California, USA,
1987–2000
Cumulative herpes zoster incidence rate for
individuals aged 10–14 years (1987–2000)
and children aged < 10 years (1987–1995)
Thomas and Hall [17] Case-control
study
Reported cases from
general practices in
south London, Uk
Dependence of herpes zoster occurence
in latently infected adults from
re-exposure to wild-type varicella zoster virus
and contacts with children
HMO, Health Maintenance Organization.
Wagenpfeil et al. Varicella vaccination and herpes zoster incidence 955
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10, 954–960
generally based on the same mathematical for-
malism of deterministic, age-structured, dynamic
population models (described in more detail
elsewhere [14,15]). However, the results can be
very sensitive to some of the input parameters,
and the model outcomes are therefore supplied
with more or less extensive sensitivity analyses.
Brisson et al. [16] presented data from the
Fourth National Survey of Morbidity in General
Practices (MSGP4). The survey included 500 000
cases from general practices in England and
Wales for the years 1991–1992. The results were
analysed with a mathematical model designed to
simulate varicella and herpes zoster incidences in
the case of a virtual varicella vaccination pro-
gramme. Special attention was given to the
relationships between vaccination, wild-type
virus spread protecting against herpes zoster,
and a potential increase of herpes zoster cases in
the initial stages of a vaccination programme.
Weekly rates of varicella and herpes zoster
incidence for England and Wales from 1976 to
1987 were analysed by Garnett and Grenfell [6].
The data comprised records from 106 doctors
collected by the Royal College of General Practi-
tioners. The findings were analysed with a
mathematical VZV model to examine the impact
of vaccination on herpes zoster incidence. This is
the only model to differentiate between the
potential of wild-type virus to boost specific
immunity and the potential of vaccine virus to
recrudesce.
Thomas and Hall [17] carried out a case-control
study in south London, UK, to estimate the
relative risk of contracting herpes zoster as a
consequence of exposure to wild-type varicella.
As in Brisson et al. [16], contacts with children
were used as a surrogate variable for virus
shedding following exposure to wild-type vari-
cella. Brisson et al. [18] simulated the impact of
vaccination on herpes zoster incidence for the
Canadian population, while Edmunds and Bris-
son [19] based their simulation on different
vaccination strategies, supplemented with a
review of published mathematical models for
varicella transmission.
The results obtained in these studies (Tables 4
and 5) concern two key issues: (1) the relationship
between wild-type virus spread and herpes zoster
incidence; and (2) the influence of a general
varicella vaccination programme on herpes zoster
incidence.
RELATIONSHIP BETWEEN WILD-
TYPE VIRUS SPREAD AND
INCIDENCE OF HERPES ZOSTER
Results concerning the relationship between wild-
type virus spread and incidence of herpes zoster
are based mainly on medical records and case
Table 2. Studies on the relationship between varicella and
herpes zoster: mathematical modelling
Study ⁄
Investigation Type Population Issues addressed
Brisson et al. [18] Simulation Canada Impact of varicella vaccination
on varicella incidence and
morbidity
Impact of varicella vaccination
on herpes zoster incidence
according to different lengths
of exposure to varicella
Edmunds and
Brisson [19]
Simulation
and review
Model Impact of varicella vaccination
on herpes zoster incidence
for different vaccination strategies
Review of published varicella
transmission dynamic models
Table 3. Studies on the relationship
between varicella and herpes zoster:
empirical and epidemiological stud-
ies combined with mathematical
modelling
Study ⁄ Investigation Type Population Issues addressed
Brisson et al. [16] Survey and
simulation
Cases from general
practices in England
and Wales 1991–1992
Age-specific incidence rates of
varicella and zoster for
adults living with and without
children in their household
Impact of varicella vaccination on
herpes zoster incidence
according to estimated length
of exposure to varicella
Garnett and Grenfell [6] Simulation
and case
reports
Cases from general
practices in England
and Wales 1976–1987
Dependencies of varicella and
herpes zoster incidences
Viral reactivation induced by varicella
Impact of varicella vaccination on
herpes zoster incidence and its
dependence on the potency of
varicella to boost specific immunity
and the recrudescence of the vaccine
virus
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reports from England and Wales, which do not
have a general vaccination programme against
varicella. Table 4 gives an overview of the essen-
tial empirical outcomes. The results of all the
studies show that living with children and close
contact with varicella cases, i.e., exposure to VZV,
are associated with a decreased incidence of
herpes zoster. However, the strength of associ-
ation varies between the studies. Thomas et al.
[17] state that protection diminishes after known
varicella contacts are controlled for. No further
information regarding the functional mechanism
of latent virus reactivation is supplied by these
studies.
INFLUENCE OF A GENERAL
VARICELLA VACCINATION
PROGRAMME ON HERPES ZOSTER
INCIDENCE
Results concerning the influence of a general
varicella vaccination programme on herpes zoster
incidence come from preliminary findings of the
first observational studies in the USA and mathe-
matical, dynamic population models. Table 5
summarises the main outcomes to date. Simula-
tion models show that if varicella boosts immu-
nity, herpes zoster incidence may increase after
the launch of a vaccination programme in the
short term, and may reach pre-vaccination levels
in the mid-term. The time-frame is sensitive to the
duration of immunity after exposure to varicella
[16]. In the long term, there is a continuous
reduction in herpes zoster incidence to far below
pre-vaccination levels as the vaccinated cohort
ages. Overall, the effects of a universal varicella
vaccination programme on herpes zoster inci-
dence depend heavily on the interaction between
varicella disease and reactivation of latent virus,
and simulations will be influenced strongly by the
assumptions made in mathematical models.
FACTORS INFLUENCING
REACTIVATION OF VZV
Very little is understood regarding the process of
reactivation of latent VZV. It is known that,
following an episode of primary varicella, VZV
becomes latent and resides in the dorsal root
ganglia. Herpes zoster, or shingles, occurs when
latent VZV reactivates, causing recurrent disease
that manifests typically as painful clusters of
small, filled vesicles with a dermatomal distribu-
tion. Factors associated with recurrent disease
include age, immunosuppression, varicella infec-
tion at a young age (< 18 months) and, for
children, intra-uterine exposure to VZV [1,20]. A
further factor suggested by Seward et al. [21]
could be subclinical VZV reactivation, with a
resulting boost in immunity and an unknown
effect on herpes zoster incidence. Additional risk
factors from epidemiological investigations, such
as genetic susceptibility, sex, ethnicity, psycholo-
gical stress and mechanical trauma, have been
summarised and discussed by Thomas and Hall
[7]. In studies of physicians in the USA with high
and low rates of contact with varicella-infected
patients [22], and of paediatricians and general
practitioners in Japan [23], a reduced risk of
herpes zoster was reported for paediatricians and
general practitioners. However, these results
should be interpreted with care, because of a
low recall rate and a small sample size, respect-
ively.
The MSGP4 data reported by Brisson et al. [16]
showed an age-dependent increase in herpes
Table 4. Key results of recent studies and one earlier
investigation: relationship between wild-type varicella
zoster virus spread and herpes zoster incidence
Study ⁄
Investigation Population Results
Brisson
et al. [16]
Cases from general
practices in
England and
Wales 1991–1992
The age-specific incidence of herpes
zoster observed in the study is similar
to that in other industrialised countries
Young adults aged 20–40 years living
with children aged < 16 years are
significantly more exposed to varicella
than those without children in their
household
People living with children aged
< 16 years are significantly protected
against herpes zoster, even after
correction for age, gender, ethnicity
or socio-economic factors
Garnett and
Grenfell [6]
Cases from general
practices in England
and Wales 1976–1987
There is no overall inverse correlation
between varicella and herpes zoster
incidence from time-series analysis
There is no seasonal pattern for zoster
At the same time (1980–1982) as
varicella incidence increased
significantly, herpes zoster incidence
decreased significantly
Indirect support for the hypothesis
that contact with varicella reduces
reactivation of latent virus
Thomas and
Hall [17]
Reported cases from
general practices in
south London, UK
Living with children protects against
herpes zoster because of increased
contact with other children outside
the household
Contact with many children outside
the household or occupational
contact with ill children are associated
with graded protection against herpes
zoster. The strength of protection
diminishes after known varicella
contacts are controlled for
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zoster incidence for groups living in a household
either with or without children. This finding is in
agreement with current knowledge and supple-
ments the observation of an increasing number of
zoster-related hospitalisations with age [9]. How-
ever, the simulation model is based on an
assumption that observed differences in herpes
zoster incidences between people living with and
without children result solely from external
boosting by varicella. Other factors, such as a
more healthy lifestyle of adults caring for chil-
dren, may also play an important role, but the
leverage is unknown. A further assumption made
by Brisson et al. [16] was the elimination of VZV
transmission in the population immediately after
the start of a vaccination campaign. The authors
concede that this leads to an overestimation of the
initial increase in the number of herpes zoster
cases for countries with a slow increase in routine
coverage rates. In the USA, the coverage rate
increased from 26% in 1997 to 68% in 2000, while
the reduction in reported varicella cases between
1995 and 2000 was from 84% to 71% [10]. A
further concern is that the data quality is difficult
to assess, because the absolute numbers of cases
are not supplied for the denoted incidence esti-
mates. The large confidence interval (CI) for the
estimated duration of immunity caused by exter-
Table 5. Key results of recent stud-
ies and one earlier investigation:
influence of a general varicella vac-
cination programme on herpes zos-
ter incidence
Study ⁄ Investigation Population Results
Ray et al. [11] HMO,
California, USA,
1994 and 2000
Overall varicella-related hospitalisations were
significantly reduced in 2000
Overall herpes zoster-related hospitalisations were
significantly increased in 2000. Age stratification showed
a significant increase in the 60+ age group, but no
significant change in the younger age groups
Gershon [5] USA There was no age-specific increasing time trend in herpes
zoster incidences from 1992 to 1999
No increase in herpes zoster incidence in the 70+ age group
has been observed to date
Goldman [12] Antelope Valley,
California, USA,
2000 and 2001
Herpes zoster incidence rates from active surveillance for
individuals aged 10–19 years are comparable to those in the
pre-licensure era
Herpes zoster incidence rates from active surveillance for
children aged < 10 years are higher than those from
historical studies or surveys in the pre-licensure era.
Comparison between surveillance data and historical studies
or surveys may, however, be biased
Goldman [13] Antelope Valley,
California, USA,
1987–2000
The herpes zoster incidence rate for individuals aged
10–14 years compares favourably with that from another
historical study
Individuals aged 10–14 years do not seem to have been
affected by increasing varicella vaccination levels to date
Brisson et al. [16] Cases from general
practices in England
and Wales 1991–1992
The simulation model predicts that the herpes zoster
incidence rate will increase for the first 20 years after
elimination of varicella transmission, peaking at an
incidence 51% higher than the pre-vaccination level. Then it
will gradually decrease, reaching the pre-vaccination level
46 years after the introduction of vaccination. In the long
term, herpes zoster incidence will continuously decrease
until it is far below the pre-vaccination level
Garnett and Grenfell [6] Cases from general
practices in England
and Wales 1976–1987
Simulation suggests that vaccination potentially increases
herpes zoster incidence only if varicella does act to boost
specific immunity, depending on the potential of the vaccine
virus to recrudesce
Brisson et al. [18] Canada If exposure to varicella has no boosting effect on the
incidence of herpes zoster, and seroconverted vaccinated
persons do not acquire herpes zoster, then herpes zoster
incidence declines as the vaccinated proportion of the
population increases
If there is a boosting effect, then herpes zoster incidence
increases significantly in the short to medium term,
depending on the duration of protection. In the long term,
herpes zoster incidence will continuously decrease until it
is far below the pre-vaccination level
Edmunds and Brisson [19] Model Determination of the long-term effects of universal varicella
vaccination depends heavily on an understanding of the
mechanisms for maintaining immunity against varicella and
herpes zoster
Targeted vaccination of susceptible adolescents and the
contacts of high-risk individuals can be effective in
preventing disease with minimal risk to the community.
However, the main benefits of universal vaccination will not
be achieved
HMO, Health Maintenance Organization.
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nal boosting, i.e., a mean of 20 years (95% CI:
7–41 years) [16], indicates a remarkably high level
of uncertainty. Overall, it seems that the simula-
tion results obtained with the model of Brisson
et al. [16] can be considered as a theoretical worst-
case scenario concerning the onset of the possible
effect. Furthermore, there is considerable uncer-
tainty with respect to the scope of the effect.
In conclusion, mathematical models cannot
substitute for, but can supplement, clinical and
epidemiological data in this scenario. They are
essential for situations that require long-term
prediction of the implications of different vaccin-
ation strategies for which empirical data cannot
be obtained in advance. The quality and validity
of predictions are heavily dependent on solid and
valid input data for the baseline time-point and
transition rates between pre-specified model com-
partments. In cases where there is much uncer-
tainty regarding some input parameters,
extensive sensitivity analyses are necessary in
order to verify the results. In addition, studies
should be initiated to examine how much of the
reactivation potency of latent VZV can be attrib-
uted to wild-type virus spread, and how much is
a result of other coexisting factors.
POTENTIAL RISKS OF
REACTIVATION FOLLOWING
VACCINATION
The possibility of a change in the epidemiology of
herpes zoster as a consequence of mass varicella
vaccination has long been recognised [6], and
surveillance systems have been established to
detect changes in herpes zoster incidence. Clinic-
ally, there is only one preliminary study [11] that
has shown an increased herpes zoster-related
hospitalisation rate in the elderly following the
introduction of mass varicella vaccination in the
USA. However, these were interim results, and
the level of vaccine coverage was not provided. In
contrast, the studies funded by the Centers for
Disease Control in Massachusetts and Seattle
have, to date, shown no increase in herpes zoster
incidence for any age group at either site [5],
which is a finding similar to that of Goldman [13].
Comparison of the herpes zoster incidence rates
reported by Goldman [12] with pre-licensing
estimates from historical studies or surveys
should be interpreted with care, because of
possible confounding factors and adjustment for
under-reporting. As these are interim data,
further results from these investigations are nee-
ded for a clearer picture.
For the special case of leukaemic children, two
clinical studies [24,25] showed that re-exposure to
VZV, either by close contact with varicella or by
vaccination, reduced the risk of contracting her-
pes zoster. However, vaccine virus seems to have
less of a tendency to reactivate than wild-type
virus, since leukaemic vaccinees were less likely
to develop herpes zoster than leukaemic children
with a history of varicella [24].
CONCLUSIONS
In summary, knowledge of the exact relationship
between varicella and herpes zoster is still
remarkably limited, although increasing efforts
to understand this relationship have been made
recently. This is true for the process and factors
influencing reactivation at an individual level, as
well as for the epidemiological situation at a
population level [7]. Additional and comprehen-
sive clinical data on the association between
varicella vaccination and herpes zoster incidence
in the elderly are essential.
Empirical data suggest that close contact with
varicella reduces reactivation of latent virus.
However, females seem to have a slightly
increased risk of contracting herpes zoster relative
to men, perhaps because of more social contacts
with children, and therefore with varicella. The
reason for this finding is unclear, and it may be
the result of combining different influencing
factors [7]. Further studies on the mechanisms of
VZV reactivation are required to determine whe-
ther and to what extent it is the result of a
combination or interaction of several factors [1,9].
In particular, no final conclusion regarding the
duration of protection can be reached from the
results of studies undertaken so far. Brisson et al.
[16] estimated that varicella exposure boosted
immunity to herpes zoster for an average of
20 years, but with a very large CI, denoting a high
degree of uncertainty in the estimation.
Surveillance studies and clinical trials to mon-
itor the potential impact of the ongoing routine
varicella vaccination programme are now well
underway in the USA. Forthcoming data will
allow the detection of changes in herpes zoster
incidence. This should allow the timely imple-
mentation of any measures necessary to avoid
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public health problems, and a vaccination pro-
gramme could be adapted accordingly [17].
The risk of an increased herpes zoster incidence
in the initial period following vaccination exists,
but the extent of this risk is unclear. If vaccination
of the elderly proves to be effective, an increase
can be avoided. A recent trial showed that
vaccination of immunocompetent patients aged
‡ 60 years is safe and immunogenic [26]. Thus, a
general vaccination programme with public
health advantages could be maintained and sup-
plemented with targeted vaccination or vaccin-
ation of the elderly if necessary. The available
evidence does not appear to justify withholding
varicella vaccination from children.
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